Tempest shareholders approve share issuance for asset purchase and extend rights plan

Tempest Therapeutics, Inc.

Approved issuance of 8,268,495 common shares for Asset Purchase Agreement with Erigen LLC and Factor Bioscience Inc.
Stockholders extended limited duration rights plan to October 10, 2026.
Amendment to 2023 Equity Incentive Plan approved, increasing share reserve by 1,410,000 shares.
Geoff Nichol elected Class I director with 1,003,845 votes for; broker non-votes 1,075,928.
Advisory say-on-pay approved with 816,856 votes for, 428,524 against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.